Table 2.

Subgroup analysis about trial duration, standard curcumin dose, and other therapy.

Subgroup and variable	Trials number	Mean difference (mg/dL) 95% CI	P	P-h
TG
Duration
>8w	5	−17.473 (−37.464, 2.517)	0.087	0.008
≤8w	4	−21.614 (−56.314, 13.086)	0.222	≤0.001
Standard curcumin dose
>100 mg/day	6	−28.944 (−49.620, −8.268)	0.006	≤0.001
≤100 mg/day	3	−18.974(−36.473, −1.474)	0.173	0.698
Other therapy
Y	5	−39.449 (−65.370, −13.527)	0.003	0.004
N	4	2.275 (−6.819, 11.369)	0.624	0.382
LDL-c
Duration
>8w	5	−2.873 (−15.134, 9.388)	0.646	0.018
≤8w	4	−5.990 (−13.292, 1.312)	0.108	0.295
Standard curcumin dose
>100 mg/day	6	−4.118 (−14.116, 5.880)	0.419	0.26
≤100 mg/day	3	−3.729 (−14.089, 6.630)	0.480	0.212
Other therapy
Y	5	−9.260 (−16.271, −2.248)	0.010	0.356
N	4	1.529 (−9.945, 13.003)	0.794	0.38
HbA1c (%)
Duration
>8w	5	−0.749 (−1.059, −0.439)	≤0.001	0.183
≤8w	3	−0.170 (-0.432, 0.092)	0.205	0.304
Standard curcumin dose
>100 mg/day	6	−0.495 (−0.777, −0.213)	0.001	0.032
≤100 mg/day	2	−0.693 (−1.711, 0.325)	0.182	0.005
Other therapy
Y	4	−0.483 (−0.735, −0.231)	≤0.001	0.337
N	4	−0.551 (−0.983, −0.120)	0.012	0.001
FBG
Duration
>8w	5	−10.893 (−21.149, −0.636)	0.037	0.054
≤8w	4	−7.620 (−14.845, −0.395)	0.039	0.234
Standard curcumin dose
>100 mg/day	6	−9.798 (−16.375, −3.221)	0.004	0.089
≤100 mg/day	3	−2.000 (−20.593, 16.592)	0.833	0.134
Other therapy
Y	5	−15.185 (−24.819, −5.550)	0.002	0.251
N	4	−5.757 (−10.871, −0.643)	0.027	0.262